Read this report for learnings from a pre-conference crash course on the foremost challenges in the NASH arena, exciting clinical updates from several phase 1 and 2 players in the ever-expanding NASH competitive landscape, and basic science galore from the world of preclinical NASH drug development.
By James Trevaskis, Principal Scientist & Head of In Vivo Pharmacology, MedImmune
By Jonathan Roth, Senior Director, In Vivo Pharmacology, Intercept Pharmaceuticals
Review discussion highlights from the meeting earlier this year.
“The goal of the three-day conference was to gather players from all corner of the growing NASH field to “help drug developers meet the unique challenges of developing a NASH drug,” but the agenda also featured many useful talks to bring attendees up to speed on the pathophysiology of the disease, areas of pressing need, and progress in drug development.”
Stephen F. Previs, Ph.D., Merck
Emil Chuang, VP, GI Therapeutic Area Head, Translational Medicine, Takeda
Download the NASH infosheet to find out about NASH drug development, 2017 market predictions and when NASH was first discovered.